Immune Thrombocytopenia
Conditions
Keywords
immune thrombocytopenia, dexamethasone, efficacy, safety
Brief summary
The project was undertaking by Qilu Hospital of Shandong University and other 7 well-known hospitals in China. In order to report the efficacy and safety of different dose dexamethasone in treating the immune thrombocytopenia (ITP).
Detailed description
The investigators are undertaking a parallel group, multicentre, randomised controlled trial of 60 adults with ITP from 7 medical centers in China. Part of the participants are randomly selected to receive dexamethasone (given at a dose of 40mg per day for 4 consecutive days) ,the others are selected to receive dexamethasone(given at a dose of 20 mg daily for 4 days). Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study. In order to report the efficacy and safety of different dose dexamethasone for the treatment of adults with immune thrombocytopenia (ITP).
Interventions
DRUGDexamethasone
Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
Sponsors
Chinese Academy of Medical Sciences
Shandong Provincial Hospital
The First Affiliated Hospital of Dalian Medical University
Peking Union Medical College Hospital
Shandong University of Traditional Chinese Medicine
Anhui Provincial Hospital
Second Hospital of Shanxi Medical University
Shandong University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Meet the diagnostic criteria for immune thrombocytopenia 2. Untreated hospitalized patients, may be male or female, between the ages of 18 \ 75 years 3. To show a platelet count \<30 \* 10\^9/L, and with bleeding manifestations 4. Willing and able to sign written informed consent
Exclusion criteria
1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 3 months before the screening visit 2. Received second-line ITP-specific treatments (eg, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) within 3 months before the screening visit 3. Received high-dose steroids or IVIG in the 3 weeks prior to the start of the study 4. Current HIV infection or hepatitis B virus or hepatitis C virus infections 5. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia) 6. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period 7. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test 8. Patients who are deemed unsuitable for the study by the investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proposed criteria for assessing early response to ITP treatments | 3 months | 1. Complete response (CR)： A platelet count ≥ 100 \* 10\^9/L measured on two occasions \> 7 days apart and the absence of bleeding. 2. Response (R)： A platelet count ≥ 30 \* 10\^9/L and a greater than two fold increase in platelet count from baseline measured on two occasions \> 7 days apart and the absence of bleeding. 3. No response (NR)： A platelet count \< 30 \* 10\^9/L or a less than two fold increase in platelet count from baseline or the presence of bleeding. Platelet count must be measured on two occasions more than a day apart. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Safety | 1 years | The type and frequency of therapy associated adverse events |
Countries
China
Outcome results
None listed